Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Kwang Jae | - |
dc.contributor.author | Son, Byoung Kwan | - |
dc.contributor.author | Kim, Gwang Ha | - |
dc.contributor.author | Jung, Hye-Kyung | - |
dc.contributor.author | Jung, Hwoon-Yong | - |
dc.contributor.author | Chung, Il-Kwun | - |
dc.contributor.author | Sung, In-Kyung | - |
dc.contributor.author | Kim, Jin Il | - |
dc.contributor.author | Kim, Jong Hyeok | - |
dc.contributor.author | Lee, Joon Seong | - |
dc.contributor.author | Kwon, Joong Goo | - |
dc.contributor.author | Park, Jung Ho | - |
dc.contributor.author | Huh, Kyu Chan | - |
dc.contributor.author | Park, Kyung Sik | - |
dc.contributor.author | Park, Moo-In | - |
dc.contributor.author | Kim, Nayoung | - |
dc.contributor.author | Lee, Oh Young | - |
dc.contributor.author | Jee, Sam Ryong | - |
dc.contributor.author | Lee, Sang Kil | - |
dc.contributor.author | Youn, Sei Jin | - |
dc.contributor.author | Kim, Sung Kook | - |
dc.contributor.author | Lee, Soo Teik | - |
dc.contributor.author | Hong, Su Jin | - |
dc.contributor.author | Choi, Suck Chei | - |
dc.contributor.author | Kim, Tae Nyeun | - |
dc.contributor.author | Youn, Young Hoon | - |
dc.contributor.author | Park, Hyo Ju | - |
dc.contributor.author | Kang, Min Ja | - |
dc.contributor.author | Park, Chi Hye | - |
dc.contributor.author | Kim, Bong Tae | - |
dc.contributor.author | Youn, Sangjun | - |
dc.contributor.author | Song, Geun Seog | - |
dc.contributor.author | Rhee, Poong-Lyul | - |
dc.date.accessioned | 2021-08-02T11:53:17Z | - |
dc.date.available | 2021-08-02T11:53:17Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2019-04 | - |
dc.identifier.issn | 0269-2813 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/14236 | - |
dc.description.abstract | Background Tegoprazan is a novel potassium-competitive acid blocker that has a fast onset of action and can control gastric pH for a prolonged period, which could offer clinical benefit in acid-related disorders. Aim To confirm the non-inferiority of tegoprazan to esomeprazole in patients with erosive oesophagitis (EE). Methods In this multicentre, randomised, double-blind, parallel-group comparison study, 302 Korean patients with endoscopically confirmed EE (Los Angeles Classification Grades A-D) were randomly allocated to either tegoprazan (50 or 100 mg) or esomeprazole (40 mg) treatment groups for 4 or 8 weeks. The primary endpoint was the cumulative proportion of patients with healed EE confirmed by endoscopy up to 8 weeks from treatment initiation. Symptoms, safety and tolerability were also assessed. Results The cumulative healing rates at week 8 were 98.9% (91/92), 98.9% (90/91) and 98.9% (87/88) for tegoprazan 50 mg, tegoprazan 100 mg and esomeprazole 40 mg, respectively. Both doses of tegoprazan were non-inferior to esomeprazole 40 mg. The incidence of adverse events was comparable among the groups, and tegoprazan was well-tolerated. Conclusion Once daily administration of tegoprazan 50 or 100 mg showed non-inferior efficacy in healing EE and tolerability to that of esomeprazole 40 mg. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Oh Young | - |
dc.identifier.doi | 10.1111/apt.15185 | - |
dc.identifier.scopusid | 2-s2.0-85062770750 | - |
dc.identifier.wosid | 000461070100003 | - |
dc.identifier.bibliographicCitation | ALIMENTARY PHARMACOLOGY & THERAPEUTICS, v.49, no.7, pp.864 - 872 | - |
dc.relation.isPartOf | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.citation.title | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.citation.volume | 49 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 864 | - |
dc.citation.endPage | 872 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | GASTROESOPHAGEAL-REFLUX DISEASE | - |
dc.subject.keywordPlus | PROTON-PUMP INHIBITOR | - |
dc.subject.keywordPlus | SYMPTOM RELIEF | - |
dc.subject.keywordPlus | LANSOPRAZOLE | - |
dc.subject.keywordPlus | OMEPRAZOLE | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | VONOPRAZAN | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | PANTOPRAZOLE | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/apt.15185 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.